Document Detail

Pelvic ultrasound examination in girls with precocious puberty is a useful adjunct in gonadotrophin-releasing hormone analogue therapy monitoring.
MedLine Citation:
PMID:  21521352     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: As there are no standard criteria for monitoring suppression during treatment of central precocious puberty (CPP) with gonadotrophin-releasing hormone analogues (GnRHa), we assessed the use of pelvic ultrasound examination for this purpose.
DESIGN/PATIENTS/MEASUREMENTS: In 31 girls with CPP, transabdominal pelvic ultrasound examination was performed before initiation of therapy with GnRHa, after approximately 3 and 6 months, at last treatment visit and after its discontinuation.
RESULTS: Three months after treatment initiation, there was a significant decrease in most uterine and ovarian parameters, with at least three parameters decreased in each patient. Endometrial echo was found in 80% of girls before therapy, in 52% (13/25) after 3 months of therapy, in 24% (6/25) after 6 months and in none on the last treatment visit (P < 0·001). In the course of treatment (mean therapy duration 2·5 ± 0·9 years), uterine parameters showed no significant change; ovarian parameters initially showed a decrease and later a modest increase although they were still smaller than before therapy. Within 3-11 months after therapy discontinuation, endometrial echo was detected in 85%, with a significant increase in uterine and ovarian parameters.
CONCLUSIONS: This prospective study indicates that comparison of individual ultrasound measurements throughout the course of treatment in girls with CPP provides a valid assessment of the suppression of the hypothalamo-pituitary-gonadal axis achieved GnRH therapy. Uterine parameters and absence of endometrial echo were found to be better indicators of adequate suppression than ovarian parameters.
Liat de Vries; Moshe Phillip
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Clinical endocrinology     Volume:  75     ISSN:  1365-2265     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-08-05     Completed Date:  2012-01-25     Revised Date:  2012-09-10    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  372-7     Citation Subset:  IM    
Copyright Information:
© 2011 Blackwell Publishing Ltd.
The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Monitoring / methods*
Follow-Up Studies
Gynecological Examination / methods
Injections, Intramuscular
Pelvis / ultrasonography*
Prospective Studies
Puberty, Precocious / drug therapy*
Time Factors
Treatment Outcome
Triptorelin Pamoate / administration & dosage,  therapeutic use*
Reg. No./Substance:
57773-63-4/Triptorelin Pamoate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Identifying metabolically obese but normal-weight (MONW) individuals in a nondiabetic Korean populat...
Next Document:  Does oral infection cause cardiovascular disease? Oral and moral challenges.